|1.||Scheller, Christian: 7 articles (01/2015 - 09/2006)|
|2.||Hänggi, Daniel: 6 articles (10/2015 - 09/2008)|
|3.||Onal, Mehmet Bulent: 6 articles (01/2011 - 10/2009)|
|4.||Macdonald, R Loch: 5 articles (10/2015 - 10/2010)|
|5.||Chen, Lin: 5 articles (06/2015 - 10/2007)|
|6.||Steiger, Hans-Jakob: 5 articles (01/2015 - 06/2006)|
|7.||Strauss, Christian: 5 articles (01/2015 - 09/2006)|
|8.||Ducros, Anne: 5 articles (01/2014 - 12/2007)|
|9.||Etminan, Nima: 4 articles (10/2015 - 01/2012)|
|10.||Gan'shina, T S: 4 articles (01/2014 - 03/2008)|
|1.||Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage)
04/01/1988 - "Nimodipine treatment was associated with a significantly better outcome (p less than 0.001): 21 (29.2%) of 72 nimodipine-treated patients had a good outcome at 3 months after subarachnoid hemorrhage (SAH) compared to eight (9.8%) of 82 placebo-treated patients. "
01/01/2014 - "Nimodipine is well characterized for the management of SAH (subarachnoid hemorrhage) and has been shown to promote a better outcome and less DIND (delayed ischemic neurological deficits). "
03/01/2009 - "In subarachnoid hemorrhage nimodipine was found effective in preventing vasospasm and thus secondary ischemic cerebral damage. "
06/01/2004 - "Intra-arterial nimodipine is effective and safe for the treatment of symptomatic vasospasm after subarachnoid hemorrhage. "
06/01/2011 - "This study evaluated the efficacy of intra-arterial nimodipine infusion for symptomatic vasospasm in patients with aneurysmal subarachnoid hemorrhage (aSAH). "
03/01/2013 - "Till date, nimodipine is the only drug with proven efficacy in preventing cerebral vasospasm. "
11/01/1987 - "In humans, a large, double-blind, placebo-controlled trial in subarachnoid haemorrhage showed that nimodipine significantly reduced the severity of neurological deficits associated with delayed cerebral vasospasm. "
12/01/2015 - "Continuous intra-arterial nimodipine infusion is an effective treatment for patients with severe cerebral vasospasm who fail to respond to HHT and oral nimodipine alone. "
05/01/2009 - "A multimodal approach with translumbar lysis in combination with kinetic therapy followed by intrathecal nimodipine lavage proved to be effective against cerebral vasospasm and for clinical outcome. "
01/01/1982 - "From its pharmacological properties nimodipine is predicted to be effective in the prevention and therapy of cerebrovascular spasm of various origins and especially in the treatment of postischaemic brain damage."
|3.||Brain Ischemia (Cerebral Ischemia)
01/01/1992 - "Our results indicate that nimodipine is effective in reducing focal cerebral ischemia, provided the MABP is maintained higher than 85 mmHg."
09/01/1988 - "These data suggest that the improved neurological outcome associated with nimodipine treatment following global cerebral ischemia does not relate to reduced levels of the prostaglandin precursor arachidonate."
08/01/2005 - "HSYA dose-dependently improved the neurological deficit scores and reduced the cerebral infarct area, and HSYA bore a similarity in potency of the therapeutic effects on focal cerebral ischemia to nimodipine. "
02/25/2000 - "Thus, nimodipine may be pharmacologically effective in preventing brain dysfunction due to cerebral ischemia in vivo."
01/01/1993 - "In the therapy of acute cerebral ischemia the therapeutic efficacy of nimodipine administered orally is not therapeutically proved until now; the intravenous administration of nimodipine offers the risk of acute hypotensive reactions. "
01/01/1995 - "In both the infarct group and the hemorrhagic stroke group, there was significant improvement as evaluated by the Matthew Scale and Barthel Index, especially in the nimodipine infusion group. "
01/01/1992 - "Planned but post hoc subgroup analysis showed a reduction in worsening frequency of 30% compared with placebo and significantly better outcome scores with 120 mg nimodipine daily started within 18 hours of stroke as measured by the Toronto scale (p less than 0.005) and when the pretreatment computed tomographic scan was negative (p less than 0.003). "
12/01/1990 - "Significantly less neurologic impairment at the end of the treatment period was documented under nimodipine treatment, and this impairment improved more in patients with moderate-to-severe stroke (baseline Mathew score less than 66) if administration of nimodipine occurred within 12 hours after stroke onset or if the patient was more than 65 years old. "
10/01/1989 - "Our data suggest that nimodipine may be beneficial in the treatment of acute stroke."
11/01/1987 - "A preliminary study of nimodipine in acute stroke showed promising results in limiting neurological disability. "
04/01/1984 - "Nimodipine, administered before or after ischemia, at doses shown to be effective in improving cerebral blood flow and in dilating central blood vessels, failed to improve either the histopathological changes or the functional deficit caused by temporary aortic occlusion in the unanesthetized rabbit."
12/01/1996 - "Nimodipine improved brain energy metabolism and blood rheology during forebrain ischemia and reperfusion in the gerbil brain."
12/01/1990 - "Our findings are compatible with the benefit of nimodipine being due to an improvement in blood flow that reduces the severity of ischemia. "
01/01/1987 - "Thus, this study revealed no beneficial effect of nimodipine when given following a 20-minute period of severe forebrain ischemia."
10/01/2013 - "BYHWD (per 6.25g/kg/d) was orally given to rats twice each day for 30 days after ischemia-reperfusion, Nimodipine (per 10mg/kg/d) was orally given to rats twice each day for 30 days. "
|2.||Calcium Channels (Calcium Channel)
|8.||L-Type Calcium Channels (Dihydropyridine Receptor)
|10.||Kainic Acid (Kainate)
|4.||Cardiopulmonary Resuscitation (CPR)